We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Partnership Agreement to Provide Funding for Studies on Immunology of Cancer

By LabMedica International staff writers
Posted on 28 Feb 2016

A partnership agreement between a Germany-based pharmaceutical company and a major Israeli research institute will ensure several years' funding for studies in the fields of immunology and immuno-oncology.

The agreement between Merck KGaA (Darmstadt, Germany) and the Weizmann Institute of Science (Rehovot, Israel) confirms the German pharmaceutical company's commitment to the Israeli institute by providing the framework for provision of funds amounting to one million euros per year for each of the next three years. The funds will be used to promote research in the fields of immunology and immuno-oncology over the initial three-year period with an option for multiple successive extensions of two years each.

Merck’s connection to the Weizmann Institute stretches as far back as 1978. Merck’s top selling multiple sclerosis drug Rebif, which had sales of 1.8 billion euros in 2014, has intellectual roots in the Weizmann Institute, as has its oncology drug Erbitux, which had sales of 900 million euros in 2014.

“We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology, and oncology as we are striving to deliver new solutions to respond to unmet medical needs,” said Stefan Oschmann, deputy CEO and vice chairman of the executive board of Merck KGaA. “We are excited that the new framework agreement will cover the first two of these three areas and are already looking forward to the proposals of the distinguished Weizmann scientists.”

“We are proud that such a fruitful relationship like the one we have with Merck has now been extended and that we have the chance to take part in creating new innovative solutions in such critical fields that so many patients globally are suffering from,” said Dr. Mudi Sheves, vice president of technology transfer at the Weizmann Institute of Science.

Related Links:
Merck KGaA
Weizmann Institute of Science

Visit expo >

Gold Member

Quality Control Material

iPLEX Pro Exome QC Panel

POC Helicobacter Pylori Test Kit
Hepy Urease Test

Hemodynamic System Monitor

OptoMonitor

8-Channel Pipette

SAPPHIRE 20–300 µL

Latest BioResearch News

Channels

Clinical Chemistry

view channel

Online Tool Detects Drug Exposure Directly from Patient Samples

Doctors often rely on patient interviews and medical records to determine what medications a person has taken, but this information is frequently incomplete. People may forget drugs they used, take over-the-counter... Read more

Image: The ARi-FL fluorescent probe offers a clearer view of tumor behavior and treatment resistance (J. Med. Chem. 2025, 68, 15, 15812-15827)

Chemical Imaging Probe Could Track and Treat Prostate Cancer

Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more

Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems

Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more

Image: Schematic diagram of esophageal cancer cell identification research process (Photo courtesy of GE Dianlong)

VOCs Show Promise for Early Multi-Cancer Detection

Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more

Molecular Diagnostics

view channel

CLIA Test Identifies Head and Neck Cancer Recurrence from Post-Surgical Lymphatic Fluid

While the lymphatic system’s critical role in metastasis has long been recognized, routine access to patient lymph has been elusive. Now, a non-invasive process can access lymph through the collection... Read more

New 15-Minute Hepatitis C Test Paves Way for Same-Day Treatment

Chronic hepatitis C infection affects an estimated 50 million people worldwide and causes around 242,000 deaths each year, largely due to cirrhosis and liver cancer. Although the infection is curable with... Read more

Ovarian Cancer Assay Outperforms Traditional Tests in Early Detection

Globally, ovarian cancer is one of the deadliest cancers affecting women. Traditionally, early diagnosis of ovarian cancer has been challenging. Many ovarian cancers are diagnosed only after they have... Read more

Ultrasensitive Method Detects Low-Frequency Cancer Mutations

Liquid biopsy has emerged as a promising approach for cancer detection and treatment monitoring, although its clinical impact has been limited by the extremely low levels of tumor-derived DNA circulating in blood.... Read more

Hematology

view channel

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Image: Sickle cell disease patients with higher levels of RMVs, AMVs, and EMVs were found to have more severe disease (Photo courtesy of Adobe Stock)

Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients

Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Immunology

view channel

Blood Test Could Detect Adverse Immunotherapy Effects

Immune checkpoint inhibitors have transformed cancer treatment, but they can also trigger serious immune-related adverse events that damage healthy organs and may become life-threatening if not detected early.... Read more

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection

Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more

Gene Signature Test Predicts Response to Key Breast Cancer Treatment

DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more

Microbiology

view channel

Blood-Based Diagnostic Method Could Identify Pediatric LRTIs

Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more

Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection

Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more

Rapid POC Tuberculosis Test Provides Results Within 15 Minutes

Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more

Pathology

view channel

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more

Image: Flowchart representing sample collections and small EV isolations from tissue, saliva, and plasma of HNC patients (A Jangholi et al., VIEW (2025). DOI: https://doi.org/10.1002/VIW.20250081)

Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer

Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more

Image: Everyday health conditions can shape Alzheimer’s blood test results (Photo courtesy of Shutterstock)

Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease

Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more

Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk

Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read more

Technology

view channel

Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read more

Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis

Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more

Image: The technology can diagnose head and neck cancer early with a drop of saliva (Photo courtesy of Adobe Stock)

AI Saliva Sensor Enables Early Detection of Head and Neck Cancer

Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more

Image: The screen-printed electrochemical sensor (Photo courtesy of UT Dallas)

AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection

Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read more

Industry

view channel

BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry

BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more

Abbott Acquires Cancer-Screening Company Exact Sciences

Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more

$Image: Freenome will evaluate Roche\'s forthcoming SBX technology for future development applications (Photo courtesy of Roche)$

Roche and Freenome Collaborate to Develop Cancer Screening Tests

Roche (Basel, Switzerland) and Freenome (Brisbane, CA, USA have entered into a strategic collaboration to commercialize Freenome's cancer screening technology in international markets.... Read more

Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.... Read more